2020 年 12 月至 2021 年 1 月，以色列医护人员的真实世界数据显示，年龄、种族、性别和既往感染状况对接受一剂 BNT162b2 mRNA COVID-19 疫苗后的免疫原性有影响。
Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021.
机构信息
Ziv Medical Centre, Safed, Israel.
These authors contributed equally to this article and share first authorship.
出版信息
Euro Surveill. 2021 Feb;26(6). doi: 10.2807/1560-7917.ES.2021.26.6.2100096.
The BNT162b2 mRNA COVID-19 vaccine showed high efficacy in clinical trials but observational data from populations not included in trials are needed. We describe immunogenicity 21 days post-dose 1 among 514 Israeli healthcare workers by age, ethnicity, sex and prior COVID-19 infection. Immunogenicity was similar by ethnicity and sex but decreased with age. Those with prior infection had antibody titres one magnitude order higher than naïve individuals regardless of the presence of detectable IgG antibodies pre-vaccination.
BNT162b2 mRNA COVID-19 疫苗在临床试验中显示出了高效力，但仍需要来自试验未纳入人群的观察性数据。我们描述了 514 名以色列医护工作者在接种第 1 剂后 21 天的免疫原性，分析因素包括年龄、种族、性别和既往 COVID-19 感染。免疫原性在种族和性别方面相似，但随年龄增长而下降。既往感染者的抗体滴度比无既往感染史者高一个数量级，无论接种前是否可检测到 IgG 抗体。
Zotero 插件